Halozyme Therapeutics Inc. buy Benchmark Co.
Start price
19.01.24
/
50%
€31.35
Target price
19.01.25
€45.94
Performance (%)
77.74%
Price
26.08.24
€55.72
Summary
This prediction is currently active. With a performance of 77.74% the BUY prediction by Benchmark_Co_ is a big success. This prediction currently runs until 19.01.25. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Halozyme Therapeutics Inc. | 0.036% | 0.036% |
iShares Core DAX® | 1.056% | 1.056% |
iShares Nasdaq 100 | -1.886% | -0.160% |
iShares Nikkei 225® | 2.553% | 4.359% |
iShares S&P 500 | -0.434% | 0.224% |
Comments by Benchmark_Co_ for this prediction
In the thread Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€49.87
08.08.24
08.08.24
€55.00
08.08.25
08.08.25
11.73%
26.08.24
26.08.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€48.68
25.06.24
25.06.24
€56.00
25.06.25
25.06.25
14.46%
26.08.24
26.08.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€36.23
16.04.24
16.04.24
€46.98
16.04.25
16.04.25
54.18%
26.08.24
26.08.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€33.23
20.10.23
20.10.23
€47.17
20.10.24
20.10.24
67.68%
26.08.24
26.08.24